BPV Huegel has advised French biotech company Valneva SE on its delisting from the Vienna Stock Exchange.
According to bpv Huegel, the delisting aims to centralize the trading of Valneva's shares on the Euronext Paris. The company's delisting was one of the first in Austria under the new delisting regime of Section 38 of the Austrian Stock Exchange Act.
Valneva SE is a biotech company developing and selling vaccines for infectious diseases with major unmet needs. The company has operations in Austria, Sweden, the United Kingdom, France, Canada, and the US.
BPV Huegel`s team was led by Partner Elke Napokoj and included Partner Michaela Pelinka and Associate David Pukel.
